Official Title
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
Brief Summary

Hospitalized patients with severe COVID-19 have an increased incidence of insulinresistance, impaired beta cell function, glucose intolerance (prediabetes), and overttype 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19negative individuals on long-term follow up.

Detailed Description

The purpose of this research study is to understand the long-term effects of COVID-19
infection on individuals without any prior history of diabetes. This study will look at
several measures of diabetes, such as glycemic control (blood glucose/sugar levels),
function of beta cells (cells that make insulin to control sugar), insulin secretion and
insulin sensitivity (fasting insulin levels).

The following participants will be enrolled: 1) have had COVID-19 infection and were
hospitalized and recovered, or 2) have had mild COVID-19 infection and were seen at
outpatient clinics or ER and were not required to be hospitalized, or 3) have not had
COVID-19 infection but were seen in outpatient clinics or ER during the same time period.

The researchers hope to learn the long-term effects of COVID-19 infection in hospitalized
patients. Specifically, they will be focusing on the subsequent development of diabetes
and associated metabolic disturbances, such as impaired insulin secretion and insulin
resistance. A relationship between COVID-19 and diabetes needs to be investigated.

Recruiting
COVID-19
Diabete Mellitus

Other: Measure of physiologic parameters

Participants will have hepatic muscle and adipose tissue insulin sensitivity tested

Eligibility Criteria

Inclusion Criteria:

- Body Mass index (BMI) < 40 kg/m2

Exclusion Criteria:

- History of diabetes prior to SARS-CoV-2 infection

- Took medications used to treat diabetes prior to SARS-CoV-2 infection

- History of myocardial infarction or stroke within 6 months

- History of major organ system disease prior to COVID-19 infection

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 75 Years
Countries
United States
Locations

Texas Diabetes Institute - University Health System
San Antonio, Texas, United States

Investigator: Andrea Hansis-Diarte, MPh
Contact: 210-567-6691
hansisdiarte@uthscsa.edu

Contacts

Marzieh Salehi, MD
(210) 567-6691
salehi@uthscsa.edu

Andrea Hansis Diarte, MPH
210-567-3208
hansisdiarte@uthscsa.edu

Ralph DeFronzo, MD, Principal Investigator
University of Texas Health Science Center San Antonio

National Heart, Lung, and Blood Institute (NHLBI)
NCT Number
Keywords
Glycemic control
Long term medical effects of COVID-19
Blood glucose control
Insulin sensitivity
MeSH Terms
COVID-19
Diabetes Mellitus